Find out more about the clinical trials with Re:Cognition Health

Register for more information about the clinical trials we have, and find out how you could make a difference in the future of healthcare discovery.

Call Now 0800 802 1030
  • Fill in your details below to get more information about our free voluntary research.

    Step 1 of 4

What to Expect

  • Step 1

    Quick pre-screening call with our patient engagement team to check which studies are suitable.

  • Step 2

    Onsite screening consultation with our experienced Doctor’s (site locations here)

  • Step 3

    If eligible, you will gain access to new medications or interventions, that have the potential to change lives.

About Clinical Trials

Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment. Last year, over 870,000 people participated in health and social care research in the UK, according to the National Institute for Clinical Research.

This is a very exciting time for research, with every study conducted we understand more about specific diseases and conditions, getting closer to finding new treatments and ultimately a cure.

Benefits of Joining a Trial

  • Trials are free and voluntary
  • Volunteers have the opportunity to help develop new treatments for future generations
  • Study volunteers get early access to new treatments for memory loss and are monitored closely throughout the trial
  • Participants get a rigorous health check including scans and we ensure your GP is kept in the loop
  • Outstanding medical care is provided at no cost, including comprehensive health screens, MRI scans and PET scans
  • The chance to avoid lengthy NHS waiting lists and access specialist private healthcare
  • Travel expenses are reimbursed for each visit and complimentary refreshments are available

Types of Trials

  • New Treatments for Memory Loss & Alzheimer’s Disease

    According to the Alzheimer’s Society over 1 million people in the UK will have a diagnosis of dementia by 2025. By 2051 this number will exceed 2 million. Worldwide it’s estimated that 82 million people will be suffering from dementia by 2030.

    Led by Dr Emer MacSweeney, an international expert in the field of Alzheimer’s research, we are passionate about finding a cure for Alzheimer’s disease. Our team of cognitive specialists offer trailblazing volunteers the opportunity to access new drugs designed to prevent the progression of memory impairment.

  • Mild Cognitive Impairment

    Mild Cognitive Impairment affects between 5-20% of people aged 65 years and over in the UK. It is not a form of dementia, however individuals with MCI often progress to developing dementia.

    Unlike dementia, MCI does not cause problems with everyday living, however individuals may require minor assistance with more demanding tasks such as driving or paying bills.

    MCI is described as a set of symptoms which may include:

    Difficulties with memory – repetition of questions, problems with short term memory and affecting recent events

    Attention –issues in focussing and being easily distracted

    Problems with problem solving – difficulties with planning or resolving issues or thinking things through

    Issues with language – struggling to find the right words

    Difficulties with visual depth perception – judging distance, problems with 3D or navigating stairs

    At Re:Cognition Health we aim to support individuals with memory loss and other symptoms of cognitive impairment through providing education, clinical excellence and access to the most advanced treatments available worldwide.

  • Much research is underway in the field of Parkinson’s disease to determine why people develop this condition, as well as new treatments to help treat its symptoms. It is thought that Parkinson’s is caused by a combination of genetic and environmental factors.

    Essentially, people with Parkinson’s disease don’t have enough of a chemical which functions as a neurotransmitter which enables certain nerve cells to send essential signals to other nerve cells. Individuals presenting with Parkinson’s Disease experience a loss of control of voluntary movements, which results from a loss of the nerve cells in the brain which make this chemical.

    Getting a diagnosis of Parkinson’s disease can be quite a complex process, as symptoms vary from person to person and many illnesses can imitate the symptoms of Parkinson’s disease.

  • ADHD/ADD is not an illness, but a condition. This means it may predispose individuals to suffer medical and psychiatric conditions like depression, anxiety, conduct disorder, and alcohol and substance abuse. However, a diagnosis of ADHD doesn’t necessarily mean that individuals will have negative outcomes later in life.

    In fact, people with ADHD have many positive characteristics! They can succeed because of their charming attitude, endless energy and vitality, creativity, problem-solving skills and empathy. With the right support, the opportunities are endless.

    Some famous people with ADHD include the singers Justin Timberlake and Solange Knowles, rapper, Olympic swimming sensation Michael Phelps, and Olympic gymnastics champion Louis Smith and businesswoman Paris Hilton. Disney empire founder Walt Disney and Nobel physicist Albert Einstein also had ADHD.

  • At present, there is no cure for Migraine. We’re working on a range of treatment options to change that. Migraines are unbelievably common in the UK, affecting up to 12 million people.

    They can be triggered by a multitude of factors ranging from genetics, food intolerance’s and allergies through to hormones, lifestyle, environment and wider medical issues.

    We’re committed to finding a cure for Migraine. The more people we have taking part in clinical trials, the more likely we are to be able to do so.

  • We recognise that neurodiversity provides fantastic benefits, as evidenced by the numerous attributes and skills exhibited by individuals living very successful lives autism.

    Adults with autism see, feel and hear the world in a unique way and this is something which nobody would ever want to change. However, sometimes adults with autism can find certain social situations challenging, at varying degrees. Whilst some individuals are content and very adept at managing these situations, others struggle and seek help and support.

    Re:Cognition Health is currently providing an opportunity for individuals who would like help to manage certain social and communication challenges, such as better control of socialisation, anxiety, stress and aggression.

  • There are three main types of MS:
    - Relapsing-remitting MS (RRMS)
    - Primary progressive MS (PPMS)
    - Secondary progressive MS (SPMS)
    - Clinically Isolated Syndrome (CIS)

    The majority of our trials are indicated for Relapsing MS therefore it is important to inform us of your diagnosis in your enquiry. The currently approved disease modifying therapies aren't a cure for MS, but they can reduce how many relapses someone has and how serious they are. They can also slow down the damage caused by relapsing multiple sclerosis that builds up over time. The studies we conduct at Re:Cognition Health are also disease modifying therapies however aiming to improve on the efficacy (the success in slowing progression and/or symptoms) than current medications used.

Learn more about the steps involved in the clinical trial volunteer process

Learn More

For information about our Long Covid Clinic

Click Here

To find out more about Re:Cognition Health

Click Here

Historical moment for Alzheimer’s treatment

Read Press Release

Speak to a member of our team

Contact Us

Our UK and USA clinics are proud to be part of the PPD Select Partnership Programme.

The Re:Cognition Health UK and US site networks are proud to be preferred sites within the PPD Select Partnership Program of Thermo Fisher Scientific’s PPD clinical research business, a global leader in clinical research.

We’re excited about the opportunities this relationship brings, and we are looking forward to working with the PPD Strategic Site Collaborations team and evolving our relationship within the PPD Select Program, across our existing ten sites.